Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Why Do Early Ovarian Cancer Detection Tests Fail?

By LabMedica International staff writers
Posted on 04 Aug 2009
Current diagnostic tests for ovarian cancer are ineffective for early detection of the disease.

A study has found that in order to significantly lower the mortality rate for the ovarian cancer, tests need to detect tumors about 200-times smaller in mass than those currently used to assess potential new tests. More...
However, the window of opportunity for treating these clinically undetectable cancers before they become life threatening is surprisingly long: about four years.

However, it is also difficult to design an effective test for this disease because there is more than one type of ovarian cancer. The most deadly, known as serous ovarian cancer, accounts for about 50 % of all cases of ovarian cancer and is responsible for at least 80 % of deaths from the disease. In contrast to other types of ovarian tumors, which can grow to be quite large before spreading to other locations, serous ovarian tumors usually metastasize before they are diagnosed.

In its early stages symptoms of ovarian cancer are vague, and often do not occur until the tumor is already several centimeters in diameter. At this point, it may have already spread to surrounding organs and tissues. Several studies have indicated that the current screening tests deliver many false-positive results and do not reduce mortality from the disease.

Biochemistry professor Patrick Brown, M.D., Ph.D. at the Stanford University, school of medicine, (Stanford, CA, USA) and team, which included scientists from the nonprofit Canary Foundation (Palo Alto, CA, USA), performed the study on early detection of ovarian cancer.

The Canary foundation is dedicated to the early detection of many types of cancer. "We are miles away from detecting the most deadly ovarian tumors at this early stage," said Prof. Brown "but now we have a chance of actually designing an effective test that will allow us to treat them before they become deadly."

Prof. Brown added that if a blood test were to be effective it would probably require identifying new markers that are not produced by normal cells. Other possible strategies might rely on new molecular imaging methods, or fluid samples from the uterus or vagina--in which tumor markers are likely to be more concentrated.

The early detection of ovarian cancer study was published in the July 28, 2009 issue of the open-access journal PLoS Medicine.

Related Links:

Stanford University, School of medicine
Canary Foundation
PLoS Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.